August 2017 Patients who initiate time-unlimited opioid-agonist therapy will generate lower average total crime-related costs over the next 6 months than patients who initiate a 21-day detoxification regimen.
March 2017 In two pilot clinical trials, buprenorphine helped participants reduce their illicit opioid use and injection drug use while awaiting admission to a methadone or buprenorphine treatment program. Researchers minimized the risks for improper use or diversion of the study medication by giving it to trial participants in a computerized, tamper-proof device that dispenses one dose each day.
New studies show that two novel compounds powerfully suppressed animals’ pain responses, while producing little or none of the respiratory depression and liability for misuse and abuse associated with morphine and other typical opioids.
Legally protected marijuana dispensaries (LMDs) were associated with lower rates of dependence on prescription opioids, and deaths due to opioid overdose, than would have been expected based on prior trends. However, LMDs also were associated with higher rates of recreational marijuana use and increased potency of illegal marijuana.
May 2016 Treatment that combines use of Bp/Nx and memantine may enable young adults addicted to opioids establish lasting abstinence after a relatively brief course of medication-assisted therapy, a pilot trial suggests.
November 2015 In the first long-term follow-up of patients treated with buprenorphine/naloxone for addiction to opioid pain relievers, half reported that they were abstinent from the drugs 18 months after starting the therapy.